Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
Healthcare
$11.43 +3.24%
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
52W Low $0.11High $3.87
Volume 0.24M
Average 19.76M
Income Statement
Follow revenue through to earnings.
Revenue
$48.47M
FY 2025 · Annual
-57.7% YoYOperating Income
-$163.25M
FY 2025 · Annual
Net Income
-$170.37M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| 74.84M | 84.57M | 225.57M | 226.23M | 228.52M | |
| 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
GOSS Earnings Waterfall · TTM
NASDAQ:GOSS · Revenue to Net Income
Key Ratios
EPS$-0.79
Gross Margin99.7%
Net Margin-328.4%
P/E Ratio-2.3
P/S Ratio31.2
Analysis
$55.5M of revenue converted into -$180.4M of net income for the selected period. Gross margin is 99.7% and net margin is -328.4%, showing how much revenue survives after costs and taxes. EPS is $-0.79, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 6, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 29, 2026 |
How much revenue does GOSS generate?
Gossamer Bio, Inc. (GOSS) reported $48.47M of revenue in fiscal 2025.
Is GOSS profitable?
Gossamer Bio, Inc. (GOSS) reported -$170.37M of net income, with a net margin of -351.5%.
Continue the stock analysis
Jump to another research area for this company.